Arialys Therapeutics develops precision small‑molecule therapies that block pathogenic anti‑NMDA receptor autoantibodies while preserving normal receptor function. Its lead candidate, ART5803, is an oral drug that restores synaptic signaling in anti‑NMDA receptor encephalitis and related autoimmune neuropsychiatric disorders, offering a targeted alternative to broad immunosuppression.
Funding
Funding not disclosed
Founders
Product
Problem
Autoimmune encephalitis caused by anti‑NMDA receptor (NMDAR) autoantibodies leads to rapid neuropsychiatric decline, seizures, and autonomic dysfunction, often requiring intensive hospital care and lacking targeted pharmacologic options. Diagnosis is frequently delayed, and existing treatments rely on nonspecific immunosuppression, which can be ineffective and carry significant side‑effects, especially in pediatric patients.
Solution
Arialys Therapeutics has developed ART5803, a precision small‑molecule therapeutic that selectively blocks pathogenic anti‑NMDAR autoantibody binding while preserving normal receptor function. The drug is based on detailed structural analysis of the autoantibody‑NMDAR interaction, enabling a mechanism‑based approach that restores synaptic signaling without broad immunosuppression. Preclinical data published in Nature Communications demonstrate reversal of antibody‑induced receptor loss and functional recovery in animal models. The company has progressed ART5803 through Phase 1 single‑ascending‑dose (SAD) and multiple‑ascending‑dose (MAD) cohorts and received FDA Rare Pediatric Disease Designation for anti‑NMDAR encephalitis, positioning it for accelerated development in this high‑unmet‑need indication.
Target Audience
Primary customers are pharmaceutical partners, academic medical centers, and specialist neurologists/psychiatrists treating patients with anti‑NMDA receptor encephalitis and related autoimmune neuropsychiatric disorders, particularly in pediatric populations.
Features
- Structure‑guided design that targets the specific epitope where pathogenic autoantibodies bind NMDAR, sparing physiological receptor activity
- Small‑molecule oral formulation enabling rapid systemic exposure and convenient dosing compared with intravenous immunotherapies
- Demonstrated reversal of antibody‑mediated receptor internalization and functional deficits in preclinical models
- First‑in‑class mechanism that modulates autoantibody‑receptor interaction rather than broadly suppressing the immune system
- Completed Phase 1 SAD and MAD cohorts with favorable safety and pharmacokinetic profiles
- FDA Rare Pediatric Disease Designation supporting accelerated regulatory pathways for pediatric anti‑NMDAR encephalitis